Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CY150112
- Development stage
- Phase 1
- Lead developer
- Jiangsu Nhwa Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CY150112 is an oral small molecule therapeutic under development by Jiangsu Nhwa Pharmaceutical for the treatment of schizophrenia. It is currently being evaluated in early-phase clinical trials to assess its safety, tolerability, and pharmacokinetic properties in healthy adult subjects. The precise mechanism of action has not been disclosed publicly, but it represents a novel approach within the antipsychotic drug development landscape.
- Other names
- CY 150112CY150112CY-150112
Beyond the preview
Go deeper on CY150112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CY150112.